Table 2.
Baseline characteristics of included participants
| N | 17 |
| Male sex, n (%) | 14 (82%) |
| Age, years | 49 (20–64) |
| Visiting friends and relatives, n(%) | 8 (47%) |
| Percentage of infected erythrocytes | 1% (0.1–40%) |
| Patients with complicated malaria, n (%) | 5 (31%) |
| Hyperparasitaemia (> 10%) | 4 |
| Shock, needing vasopressor support | 1 |
| Spontaneous bleeding | 1 |
| Haemoglobinuria | 1 |
| Acute kidney injury | 1 |
| GCS at presentation (median, range) | 15 (12–15) |
| Neurological symptoms at presentation, n(%) | |
| Headaches | 7 (41%) |
| Aphasia | 2 (12%) |
| Disorientation | 2 (12%) |
| Somnolence | 1 (6%) |
| Haemoglobin at presentation, g/dl | 13.1 (10.3–15.7) |
| White blood count at presentation, /µl | 4.8 (3.7–10.3) |
| Thrombocyte count at presentation, /µl | 61 (11–209) |
| Treatment regimens, n (%) | |
| Artesunate, followed by Atovaquone/proguanil | 5 (29%) |
| Dihydroartemisinin/piperaquine | 6 (35%) |
| Atovaquone/proguanil | 5 (29%) |
| Mefloquine | 1 (6%) |
Values represent median and range, unless otherwise specified